Baba Vanga was right? Scientists claim alien ship larger than Manhattan, moving at 1.3 lakh mph, to attack Earth this Nov
Baba Vanga had reportedly predicted
that humanity would make contact with aliens in 2025. But recent scientific claims suggest that contact may come sooner — and far more hostile.
According to a report published on July 16 on the preprint server arXiv and cited by the
New York Post
and South West News Service, a team of scientists has warned that an alien spacecraft may be heading toward Earth — potentially launching an attack as early as this November.
Explore courses from Top Institutes in
Please select course:
Select a Course Category
Cybersecurity
CXO
MCA
Data Analytics
others
Technology
MBA
PGDM
Finance
Data Science
Project Management
Product Management
Leadership
Public Policy
Artificial Intelligence
Others
Design Thinking
Digital Marketing
Degree
Operations Management
Healthcare
Data Science
Management
healthcare
Skills you'll gain:
Duration:
10 Months
MIT xPRO
CERT-MIT xPRO PGC in Cybersecurity
Starts on
undefined
Get Details
The object in question, named 3I/ATLAS, was first detected on July 1 and is racing toward the Sun at over 130,000 miles per hour. Just a day after its discovery, astronomers confirmed that it originated from outside our solar system. Initial observations suggested it might be a comet, roughly 15 miles in diameter — making it even larger than Manhattan.
However, in their paper, researchers Avi Loeb, Adam Hibberd, and Adam Crowl from the Initiative for Interstellar Studies propose that 3I/ATLAS might not be a natural object at all, but rather a piece of extraterrestrial spy technology in disguise.
Loeb, a Harvard astrophysicist known for his controversial theory that the 2017 object `Oumuamua could have been an alien reconnaissance probe, argues that 3I/ATLAS displays several unusual characteristics — including a unique trajectory and exceptionally high speed. These anomalies, he suggests, could point to an intelligent origin.
Live Events
In a blog post, Loeb noted that the object's path through the solar system allows it to pass close to Jupiter, Mars, and Venus — an ideal opportunity, he says, for aliens to covertly deploy surveillance 'gadgets' on these planets.
What's more concerning is that when 3I/ATLAS reaches its closest point to the Sun (perihelion) in late November, it will temporarily vanish from Earth's view. Loeb suggests this may be a deliberate move to avoid detection by Earth-based telescopes — possibly the moment when alien technology could be dispatched toward our planet.
If 3I/ATLAS is indeed a technological artifact, it may support the "dark forest hypothesis" — the idea that intelligent alien civilizations stay hidden to avoid detection by potential threats.
Loeb warns that this situation might not just be surveillance, but a precursor to a potential
alien attack
, urging that "defensive measures" may need to be considered.
Whether this object turns out to be a comet or a cosmic Trojan horse, the scientific world — and the public — will be watching closely as November approaches.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
United News of India
2 hours ago
- United News of India
INDO-US satellite NISAR will start scientific operations after 90 days
Chennai, July 28 (UNI): The highly anticipated NASA-ISRO Synthetic Aperture Radar (NISAR) satellite, a collaborative Earth observation mission between the United States and India, is slated for launch on July 30 at 5:40 pm IST. The 2,400 kg satellite will be carried into orbit by ISRO's Geosynchronous Satellite Launch Vehicle-F16 (GSLV-F16) from the Satish Dhawan Space Centre in Sriharikota, Andhra Pradesh. However, ISRO has clarified that while the launch is imminent, NISAR's dedicated scientific operations will not begin until approximately three months after it is successfully placed in orbit. This initial period will be critical for preparing the advanced observatory. According to ISRO, the NISAR mission is structured into distinct phases. Following the Launch Phase on July 30, the satellite will enter its Deployment Phase. This crucial stage involves the complex in-orbit unfurling of NISAR's 12-meter diameter reflector, a key component developed by NASA's Jet Propulsion Laboratory (JPL), which will extend 9 meters away from the satellite. Subsequently, the mission will enter a 90-day Commissioning Phase, also known as "In-Orbit Checkout (IOC)." This period is solely dedicated to meticulously preparing the observatory for its scientific tasks. It will involve initial checks and calibrations of the satellite's core systems, followed by a thorough engineering checkout of the payload and instruments by JPL. Only after the successful completion of this commissioning phase will the Science Operations Phase commence, extending for the duration of the mission's life. During this phase, NISAR's science orbit will be precisely maintained through regular maneuvers, strategically planned to minimize interference with scientific observations. Extensive calibration and validation (CalVal) activities will also be ongoing. The detailed observation plan for both the L-band and S-band instruments, along with all necessary engineering activities, are being meticulously generated prior to launch through continuous coordination between JPL and ISRO. NISAR is poised to be a groundbreaking mission, providing unprecedented, high-resolution, all-weather, day-and-night data to observe Earth's changing ecosystems, dynamic surfaces, and ice masses. This data is expected to revolutionize our understanding of natural hazards like earthquakes, tsunamis, volcanoes, and landslides, as well as providing critical information for studies on climate change, agriculture, and water resources. UNI VJ AAB
Mint
2 hours ago
- Mint
Indian contract drug makers timed their IPOs right. But is the business worth the premium?
An anticipated shift in the global pharmaceutical supply chain away from China has investors excited about Indian contract research, development and manufacturing organisations (CRDMOs), companies that offer services from early-stage drug discovery to late-stage drug development. Export-focused CRDMOs including Anthem Biosciences, Sai Life Sciences and Divi's Laboratories are trading at expensive valuations, reflecting investor enthusiasm as innovator drug companies look at diversifying and derisking their operations. However, experts cautioned that while CRDMOs are expected to post high growth, their financial performances have yet to reflect it. Bengaluru-based Anthem Biosciences made a stellar debut on the stock exchanges on 21 July, listing on the National Stock Exchange at a premium of 27 percent over its initial public offering price of ₹ 570. The IPO, with an issue size of ₹ 3,395.79 crore, was subscribed 67.42 times. Anthem's stock traded at a price-to-earnings (PE) ratio of 93.24 on 25 July. 'The good news is that… China is a behemoth. So, we have that much headroom to grow,' Ajay Bhardwaj, managing director and chief executive officer, told Mint earlier. About 65% of India's imported bulk drugs and advanced drug intermediates worth $3.5 billion in FY25 came from China, according to the commerce ministry. The government wants to strengthen local manufacturing through an upgraded drugs production-linked incentive scheme as it pushes for self-sufficiency in bulk drugs that go into manufacturing medicines. The Indian CRDMO industry today is worth $3-3.5 billion, making up only 2-3% of the global CRDMO market, which is worth $145 billion. It grew at a compound annual growth rate of 15% from 2019-2024, according to a recent report by BCG and IPSO. The industry is at a tipping point, with strong fundamentals and massive headroom to grow, fueled by competitive advantage in small molecule capabilities, faster startup time, focus on quality and cost advantages, the report noted. Unlike CRDMOs, CDMOs (contract development and manufacturing organisations) are typically involved in manufacturing already commercialised drugs. Sai Life Sciences, which made its market debut in December 2024, traded at ₹ 837 on 25 July, close to its high of about ₹ 851, valuing the company at roughly 102 times trailing earnings and about 8.2 times book value. Divi's Laboratories and Syngene International also traded at premiums, at a PE ratio of 80.31 and 55.09, respectively. In comparison, generic pharmaceutical giants are valued relatively modestly: Sun Pharmaceutical Industries trades at a PE ratio of 37.37, Dr Reddy's Laboratories at 18.84, and Cipla at 23.53. Sai Life Sciences shares are up over 18% since listing on the NSE. Divi's Laboratories gained 35.56% from 30 July 2024 to 28 July 2025, Piramal Pharma rose 20.36%, while Syngene International's shares were down 12.72%. Syngene International, a unit of biopharmaceutical company Biocon, kicked off this fiscal's earnings season last week. It posted an 11% year-on-year rise in revenue from operations to ₹ 875 crore for Q1, a robust start compared to its FY25 performance (4% revenue growth YoY). The management maintained its expectation of revenue growth in the mid‑teens for FY26. Sai Life Sciences delivered 16% revenue growth to ₹ 1,695 crore in FY25. Divi's reported a 19% year-on-year rise in full-year revenue to ₹ 9,360 crore in FY25, while net profit surged 37% to ₹ 2,191 crore. Divi's is expected to post revenue growth of 18% year-on-year in Q1FY26, according to brokerage BNP Paribas. 'The Indian CDMO sub-sector presents a highly promising opportunity as investors view it as a direct beneficiary of the China+1 thematic,' Sunil Khaitan, managing director leading financing in India at Goldman Sachs, told Mint. 'We expect the capital markets activity in this space to further accelerate over the next 6-12 months.' The China-plus one theme – to diversify supply chains and reduce overdependence on China – is a key driver, but it's not just that. CRDMOs are on an aggressive capacity expansion track as they anticipate winning over more clients in the future and bank on technological niches to cater to biotech companies as demand for new technologies and drugs grows. Anthem has expertise in new chemical entities as well as biologics (drugs made from living organisms or their components) and capabilities to work on RNAi (a gene regulatory mechanism), antibody drug conjugates that target and kill cancer cells, peptides (short chains of amino acids), lipids, and oligonucleotides (synthesised nucleic acids). OneSource Specialty Pharma, a subsidiary of Strides Pharma, which listed in January, expects its focus on niche areas such as biologics, drug substances, injectables, and drug-device combinations to drive growth. Its offerings in drug-device combinations, particularly for GLP-1s (hormones that regulate blood sugar levels), which are often sold in pen-filled devices, is expected to be a major growth opportunity. 'We are currently executing a 5x expansion of our cartridge-filling capabilities to meet our customer demand and which will significantly boost future revenue,' CEO Neeraj Sharma told Mint in an emailed response. Anthem Biosciences and Sai Life Sciences did not respond to Mint's queries. Investors are looking at CRDMOs not just for potential growth driven by these tailwinds but also as diversification of their portfolios, experts said. Opportunities in traditional pharma companies with a focus on domestic formulations and US generics are drying up because of a slowdown in new approvals and regulatory issues. 'The investor would like to have exposure to companies and segments which have the potential for high growth and themes of shifting manufacturing from China to India,' Tausif Shaikh, healthcare and pharma analyst at BNP Paribas, told Mint. While CRDMOs have reported steady, mid-teen revenue growth, their performance has not been encouraging enough even as valuations remain expensive, Shaikh pointed out. Unlike sectors such as healthcare services, where one can gauge a company's performance based on metrics like hospital bed occupancy and average revenue per bed, for contract drug manufacturers, management commentary is the main indicator of the company's expected growth and performance, said Shaikh. Most companies report an uptick in interest from innovators to hire their services and have embarked on aggressive capacity expansion. Syngene plans to boost its biologics manufacturing footprint in FY26 through its newly acquired US facility for $36.5 million. Divi's Laboratories is undertaking a ₹ 650-700 crore capacity expansion at its existing facilities, while Sai Life Sciences has completed the second phase of its Bidar Unit IV capacity expansion for small-molecule active pharmaceutical ingredients and intermediates. On the back of this, the growth outlook remains strong. "Earnings are expected to be strong for export-oriented CDMOs for the next 2-3 years considering the capex projects and potential addition of new molecules,' Shrikant Akolkar, pharma equity research analyst at brokerage Nuvama, told Mint. However, the CDMO business is non-linear, Akolkar said, adding that one must pay attention to the annual performance and not a couple of quarters of number misses.
Time of India
5 hours ago
- Time of India
Isro-Nasa Earth observation satellite to be launched on July 30
Isro-Nasa Earth observation satellite to be launched on July 30 CHENNAI: The Indian space research organisation (Isro) is gearing up for a series of exciting missions. According to the organisation's chief, Dr V Narayanan, Isro will launch the Nasa-Isro Synthetic aperture radar (NISAR) satellite on July 30 using the GSLV-F16 rocket . This satellite will scan the entire globe every 12 days, providing high-resolution, day-and-night, all-weather imagery across a 242 km swath. NISAR aims to support climate change research, disaster response, and Earth science studies. "We are going to launch the Nasa-Isro Synthetic aperture radar (NISAR) satellite through the GSLV-S16 rocket by July 30th," said the Isro chief. Nisar features Nasa's L-band and Isro's S-band radar, enabling it to track surface changes with centimeter-level precision. The satellite will systematically map Earth's surface, monitoring dynamic processes like glacier retreat, vegetation changes, and earthquakes. NISAR will deliver high-resolution data crucial for monitoring natural disasters, environmental degradation, and infrastructure stress. Narayanan also provided an update on the Gaganyaan Mission, which aims to send Indian astronauts into space. Before the crewed mission, Isro will conduct three uncrewed missions, including the Humanoid Mission. In December, a robot called Vyommitra will be sent into space to test the systems. Two uncrewed missions: If the humanoid mission is successful, two more uncrewed missions will be launched next year. Following the completion of all tests, the Gaganyaan Mission is scheduled to launch in March 2027. "We will conduct three uncrewed missions before the Gaganyaan mission. In December, a humanoid mission will be conducted, during which a robot called Vyommitra will be sent into space. If it's successful, then two uncrewed missions will be launched next year. After all the tests in March 2027, as PM Modi said, Gaganyan Mission will be launched," added the Isro chief. Vyommitra is a name derived from two Sanskrit words: "Vyoma" (meaning "space") and "Mitra" (meaning "friend"). This female robot astronaut is equipped with the capability to monitor module parameters, issue alerts, and execute life support operations. It can perform tasks such as operating six panels and responding to queries. These missions demonstrate India's growing capabilities in space exploration and technology, with Isro playing a vital role in advancing the nation's vision of self-reliance and global leadership in space.
